Interestingly, the ability of SGLT2i to reduce inflammatory cytokines in patients with cardiovascular disease was implicated with the inactivation of NLR family pyrin domain containing 3 (NLRP3) inflammasome by SGLT2i via ketone bodies [7]. This evidence concerns the gene NLRP3 and cardiovascular disorder.